Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The long-term landscape for large-volume infusion and intermediates is stable, and the innovative drugs have market potential overseas [5] - The company has a strong competitive position in the large-volume infusion market and is expected to achieve significant cost reductions in 2025 [7] - The company has a leading global ADC research platform, with substantial potential in overseas markets [7] - The company is transitioning successfully from generics to innovation, with significant R&D investments expected to yield results [7] - The forecasted net profit for 2025-2027 is 27.4 billion, 33.7 billion, and 39.6 billion RMB, with corresponding growth rates of -6.7%, 23.2%, and 17.5% [7] Financial Summary - The company's revenue for 2023 is projected at 21,454 million RMB, with a year-on-year growth rate of 13.44% [6] - The net profit for 2023 is estimated at 2,456 million RMB, reflecting a year-on-year growth of 43.74% [6] - The earnings per share (EPS) for 2023 is expected to be 1.54 RMB [6] - The company’s total market capitalization is approximately 57,865.51 million RMB, with a closing price of 36.21 RMB [3][4]

科伦药业（002422）今日涨停，成交额14.46亿元，换手率3.22%，盘后龙虎榜数据显示，深股通专用席位买入6740.65万元并卖出 8094.31万元，3家机构专用席位净买入1.32亿元，有3家机构专用席位净卖出1.29亿元。 | > 龙虎榜 | | | | Q、输入问句,你想知道的都在这里 | | 开始搜索 | | --- | --- | --- | --- | --- | --- | --- | | 2025-04-30 2025-04-01 | 2024-09-20 | | | | | 历史龙虎榜信息>> | | 上榜原因:日涨幅偏离值达7%的证券 | | | | | | 更多个股解读>> | | 营业部名称 | | 买入金额(元) | 占总成交比例 | 卖出金额(元) | 占总成交比例 | 净额(元) | | 深股通专用 | | 6740.65万 | 4.66% | 8094.31万 | 5.60% | -1353.66万 | | 申万宏源证券有限公司上海闵行区东川路证券营业部 上海超短 | | 5421.80万 | 3.75% | 1.09万 | 0.00% | 5420.71万 | | 机构 ...

创新药概念持续活跃 百济神州等多股创历史新高 智通财经4月30日电，百济神州、诺诚健华、锦波生物均创出历史新高，科伦药业、益方生物、泽璟制 药、华东医药、恒瑞医药等涨幅靠前。消息面上，2025年一季度，已经出现了超20笔涉及中国药企全球 授权的交易，BD交易有望在今年再创新高。 ...

Policy Developments - Hainan Province has released a plan to enhance the quality of generic drugs, supporting the expedited registration and market entry of first generic products, particularly those that are urgently needed in clinics or have high prices or supply shortages [1] - The plan includes strengthening supervision of entrusted production and supporting consistency evaluations for the quality and efficacy of generic drugs, which will improve overall drug quality and ensure public safety [1] Drug and Device Approvals - Huasheng Technology's Sanqi Tongshu Capsules have been approved as the first secondary protected traditional Chinese medicine by the National Medical Products Administration, enhancing the company's core competitiveness in treating cardiovascular diseases [2] - United Imaging Healthcare's digital subtraction angiography system (DSA) uAngioAVIVA has received FDA approval, marking it as the first and only domestic DSA device allowed in the U.S. market [3] - Warner Pharmaceuticals has received a listing approval notice for potassium sulfate, which will enrich the company's product line and enhance its core competitiveness [4] - Xinhua Medical has obtained a Class II medical device registration certificate for its multi-chamber cleaning and disinfection device, which significantly reduces processing time compared to fully automatic devices [5] Financial Reports - Kelun Pharmaceutical reported a 29.42% year-on-year decline in revenue for Q1 2025, totaling 4.389 billion yuan, with a net profit decrease of 43.07% to 584 million yuan [6][7] - AstraZeneca's Q1 2025 revenue reached $13.588 billion, a 10% increase year-on-year, driven by double-digit growth in oncology and biopharmaceuticals [8] Capital Market Activities - Koser Medical Technology has completed nearly 100 million yuan in B+ round financing, which will be used for core product development and global market expansion [9] - Xellar Biosystems has secured several million yuan in strategic investment from XtalPi, aimed at accelerating the development of its organ-on-chip technology and expanding international collaborations [10] Industry Developments - Chen Yuqing has been appointed as the new chairman of Fosun Pharma, succeeding Wu Yifang, and will oversee the company's strategic development and organizational growth [11] - Merck has announced a $1 billion investment to build a production facility in Wilmington, Delaware, aimed at producing the next generation of biopharmaceuticals, including Keytruda [12] - Prilenia has entered a collaboration agreement with Ferrer for the oral sigma-1 receptor agonist Pridopidine, with a total deal value of up to €500 million [13] - Junshi Biosciences has signed a licensing agreement with Sandoz for its HLX13 monoclonal antibody, receiving an upfront payment of $31 million and potential milestone payments totaling $1.6 billion [14] Public Sentiment Alerts - Medici has announced that major shareholder Chen Jianhuang plans to reduce his stake by up to 2.23% between May 26 and August 25, 2025, due to personal funding needs [15]

智通财经4月29日电，科伦药业(002422.SZ)公告称，科伦药业发布2025年第一季度报告，营业收入为 43.89亿元，同比下降29.42%；归属于上市公司股东的净利润为5.84亿元，同比下降43.07%。 科伦药业：一季度净利润为5.84亿元 同比下降43.07% ...

Financial Performance - The company's revenue for Q1 2025 was ¥4,389,897,045, a decrease of 29.42% compared to ¥6,219,417,413 in the same period last year[5] - Net profit attributable to shareholders was ¥584,242,512, down 43.07% from ¥1,026,188,176 year-on-year[5] - Basic and diluted earnings per share were both ¥0.37, reflecting a decline of 44.78% from ¥0.67 in the same period last year[5] - Total operating revenue decreased to ¥4,389,897,045, down 29.5% from ¥6,219,417,413 in the previous period[24] - Net profit for the period was ¥659,587,476, representing a 48.7% decrease from ¥1,285,801,413 in the prior year[25] - The total comprehensive income for the period was CNY 653,323,410, a decrease from CNY 1,284,956,201 in the previous period[26] Cash Flow - The net cash flow from operating activities decreased by 64.86%, amounting to ¥449,384,244 compared to ¥1,278,763,116 in the previous year[10] - Net cash flow from operating activities was CNY 449,384,244, significantly lower than CNY 1,278,763,116 in the previous period[28] - Cash inflow from operating activities totaled CNY 5,184,117,253, compared to CNY 6,561,069,026 in the previous period[27] - Cash outflow from operating activities was CNY 4,734,733,009, down from CNY 5,282,305,910 in the previous period[27] - Net cash flow from investing activities was negative CNY 690,071,360, a decline from positive CNY 670,633,809 in the previous period[28] - Cash inflow from investing activities was CNY 4,018,350,908, compared to CNY 1,772,849,022 in the previous period[28] - Cash outflow from financing activities was CNY 1,063,394,172, down from CNY 1,512,332,605 in the previous period[28] - The ending balance of cash and cash equivalents was CNY 4,075,118,403, down from CNY 6,231,493,756 in the previous period[28] Assets and Liabilities - Total assets increased by 1.37% to ¥37,826,228,881 from ¥37,316,259,482 at the end of the previous year[5] - Current liabilities totaled ¥9,092,533,232, slightly down from ¥9,137,877,768, a decrease of 0.5%[23] - Long-term borrowings decreased to ¥196,000,000 from ¥342,000,000, a reduction of 42.8%[23] - The company's equity attributable to shareholders increased to ¥23,094,459,078, up from ¥22,479,520,446, a rise of 2.7%[23] Investment and Income - Investment income decreased by 45.17%, amounting to ¥61,314,415 compared to ¥111,835,302 in the previous year[9] - The company reported an increase in investment income to ¥61,314,415 from ¥111,835,302, a decline of 45%[25] - The company reported a total investment of 10,000 million in structured deposits with a floating return of 2.50%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 33,389[11] - Liu Gexin holds 23.72% of the shares, totaling 379,128,280 shares, with 284,346,210 shares under lock-up and 106,014,000 shares pledged[11] - The second largest shareholder, Yaan State-owned Assets Management Co., Ltd., holds 6.07% of the shares, totaling 96,983,174 shares, with 34,010,800 shares pledged[11] - The top 10 shareholders collectively hold significant stakes, with the largest shareholder holding nearly 24%[11] - The company has no preferred shareholders as of the reporting period[12] Research and Development - The company has received approval for its subsidiary's PD-L1 antibody, indicating progress in its product pipeline[18] - A new drug application for the core product, Boduqumab, has been accepted by the National Medical Products Administration, highlighting ongoing R&D efforts[18] - The company has established an exclusive licensing agreement for SKB378/HBM9378, which may enhance its market position[18] Financial Management - The company did not engage in any significant financial management activities during the reporting period[12] - The company plans to continue its financial management strategy, including potential future entrusted wealth management plans[21] Miscellaneous - The company reported a total of 424,982,000.00 in financial assets, with a significant increase in cash and cash equivalents to 4,092,787,913.00 from 3,973,908,715.00[21] - The trading financial assets rose to 2,231,249,987.00, up from 1,921,163,411.00, indicating a growth of approximately 16.2%[21] - Accounts receivable decreased slightly to 4,726,326,218.00 from 4,795,035,595.00, reflecting a reduction of about 1.4%[21] - Inventory levels increased to 3,827,874,323.00 from 3,800,617,271.00, showing a growth of approximately 0.7%[21] - The company completed the cancellation of repurchased shares, indicating a strategic move to enhance shareholder value[19] - The company's first quarter report was not audited[29]

Group 1 - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7459.13 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 3.80% over the past month, increased by 3.37% over the past three months, and has risen by 0.20% year-to-date [1] - The CSI 300 Index categorizes its 300 sample stocks into 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] Group 2 - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: Heng Rui Medicine (24.67%), WuXi AppTec (16.06%), Pian Zai Huang (6.84%), Yunnan Baiyao (5.71%), Kelun Pharmaceutical (4.69%), New Horizon (3.81%), East China Pharmaceutical (3.6%), Shanghai Raist (3.44%), Fosun Pharma (3.37%), and Changchun High-tech (3.18%) [1] - The market share of the CSI 300 Pharmaceutical and Biotechnology Index is 63.43% from the Shanghai Stock Exchange and 36.57% from the Shenzhen Stock Exchange [2] - The industry composition of the index includes: chemical drugs (42.67%), pharmaceutical and biotechnology services (21.27%), traditional Chinese medicine (19.68%), and biological drugs (16.38%) [2] Group 3 - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted along with the sample adjustments, which are generally fixed until the next scheduled adjustment [2] - Temporary adjustments occur when the CSI 300 Index samples are modified, and changes in industry classification due to special events will also lead to corresponding adjustments in the CSI 300 industry index [2]

Core Points - The Shanghai Composite Index opened lower and the CSI 300 Pharmaceutical and Biotechnology Index reported 7479.61 points [1] - The CSI 300 Pharmaceutical and Biotechnology Index has decreased by 0.64% in the past month, increased by 3.66% over the last three months, and has risen by 0.48% year-to-date [1] Industry Composition - The CSI 300 Pharmaceutical and Biotechnology Index is composed of 11 primary industries, 35 secondary industries, over 90 tertiary industries, and more than 200 quaternary industries [1] - The index is based on the performance of all securities in the CSI 300 Index classified by industry, with a base date of December 31, 2004, and a base point of 1000.0 [1] Index Holdings - The top ten holdings in the CSI 300 Pharmaceutical and Biotechnology Index are: - Heng Rui Medicine (24.75%) - WuXi AppTec (15.82%) - Pian Zai Huang (6.85%) - Yunnan Baiyao (5.7%) - Kelun Pharmaceutical (4.68%) - New Horizon (3.79%) - East China Pharmaceutical (3.64%) - Shanghai Raist (3.44%) - Fosun Pharma (3.38%) - Changchun High-tech (3.17%) [1] Market Distribution - The market distribution of the CSI 300 Pharmaceutical and Biotechnology Index shows that the Shanghai Stock Exchange accounts for 63.33% and the Shenzhen Stock Exchange accounts for 36.67% [2] Sector Breakdown - The sector breakdown of the index holdings indicates that: - Chemical drugs account for 42.69% - Pharmaceutical and biotechnology services account for 21.06% - Traditional Chinese medicine accounts for 19.74% - Biological drugs account for 16.51% [2] Sample Adjustment - The index samples are adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are adjusted in accordance with sample changes, and any special events affecting a sample company's industry classification will lead to corresponding adjustments in the index [2]

Core Viewpoint - Sichuan Kelun Pharmaceutical Co., Ltd. is set to hold its 2024 annual performance briefing on May 6, 2025, to provide insights into its financial performance and address investor inquiries [1][4]. Group 1: Event Details - The annual performance briefing will take place from 15:00 to 17:00 on May 6, 2025, via a text Q&A format on the Jinmen Finance platform [1]. - Investors can participate in the briefing through a designated online link [2]. Group 2: Participants - Key attendees at the briefing will include Chairman Liu Gexin, Independent Director Ren Shichi, Vice General Manager and CFO Lai Degui, Vice General Manager and Board Secretary Feng Hao, Sales Head Ge Tao, CFO of Kelun Botai and Board Secretary Zhou Zejian, and Deputy General Manager and Board Secretary of Chuaning Bio Gu Xiang [2]. Group 3: Investor Engagement - The company is actively soliciting questions from investors prior to the event to ensure that common concerns are addressed during the briefing [2].

本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 四川科伦药业股份有限公司（以下简称"公司"）将于 2025 年 5 月 6 日（星 期二）下午 15:00-17:00 在进门财经以文字问答的形式举行科伦药业 2024 年度业 绩说明会。 投资者可以通过以下两种方式参与： 1）电脑端参会：https://s.comein.cn/syfe7cqa； 2）登录进门财经 APP/进门财经小程序，搜索"002422"、"科伦药业"或者 扫描二维码，进入"科伦药业（002422.SZ）2024 年度网上业绩说明会"，点击进 入会议。 证券代码：002422 证券简称：科伦药业 公告编号：2025-037 四川科伦药业股份有限公司 关于召开 2024 年度网上业绩说明会的公告 为广泛听取投资者的意见和建议，解答投资者关切的问题，现就公司2024年 度业绩说明会提前向投资者公开征集问题。提问通道自本公告发出之日起开放， 投资者通过上述参与方式进入"科伦药业2024年度网上业绩说明会"页面进行 提问，公司将在本次业绩说明会上对投资者普遍关注的问题进行回答。 1 欢迎广大投资者积 ...